2022.04.27
Completion of the Series C funding to advance pipeline of novel GPCR antibodies
NBHL has completed 7.64 million USD of the Series C funding to advance pipeline of novel GPCR antibodies.
Click here for detail.
News archives 2022.04
Home > 2022.04
- Recent Posts
- Completion of the Series C funding to advance pipeline of novel GPCR antibodies
- Announcement of a grant of patent for innovative new high-throughput single-cell analysis technology in US 2022.03.29.
- NBHL will participate in BIO-Europe Spring 2022 – Digital.
- NBHL will participate in GLOBAL START UP CONNECTION JAPAN and Digital RESI
- NBHL will participate in Botech Showcase (Vertual).
- Closing of the Series C funding to advance pipeline of novel GPCR antibodies
- Announcement of Agreements with ReCentrics Biotechnology Co. Ltd. and NBHL for Global Collaboration to Development and Commercialize GPCR Antibody Therapies
- NBHL will participate in BIO-Europe 2020 – Digital.
- NBHL will be present at BioJapan 2020 in Yokohama, Japan
- NBHL will participate in BioPharm America 2020 – Digital
- NBHL will attend Discovery on Target 2020 – Virtual.
- NBHL will participate in ChinaBio Partnering Forum 2020 – Digital
- No opposition filed against NBHL’s European patent for anti-CCR7 antibodies
- NBHL announces poster presentation at Antibody Engineering & Therapeutics Asia 2020 in Kyoto, Japan
- NBHL will attend BIO CEO & Investor Conference 2020 in New York, USA
- NBHL to present at Antibody Engineering & Therapeutics 2019 in San Diego, USA
- NBHL will attend BIO-Europe 2019 in Hamburg, Germany.
- NBHL will attend BIO Investor Forum 2019 in San Francisco, USA
- NBHL to present at the FESTIVAL OF BIOLOGICS 2019 in Basel, Switzerland
- NBHL will be present at BioJapan 2019 in Yokohama, Japan
- Past log
- 2022.4
- 2022.3
- 2022.1
- 2021.8
- 2020.10
- 2020.9
- 2020.8
- 2020.4
- 2020.2
- 2019.12
- 2019.11
- 2019.10
- 2019.9
- 2019.5
- 2019.3
- 2018.10
- 2018.8
- 2018.3
- 2016.11
- 2016.9
- 2016.7
- 2016.6
- 2016.5
- 2016.3
- 2015.9
- 2014.11
